Tafenoquine for children: a step towards implementation

Published: February 1, 2022


Commons RJ, Price RN. Tafenoquine for children: a step towards implementation. Lancet Child Adolesc Health. 2022 Feb;6(2):72-73. doi: 10.1016/S2352-4642(21)00375-8. Epub 2021 Dec 3. PMID: 34871571.


After several decades of development, tafenoquine, an 8-aminoquinoline compound, was registered by the US Food and Drug Administration on July 20, 2018, as a single-dose regimen for the prevention of Plasmodium vivax malaria relapse and weekly regimen for the chemoprophylaxis of malaria. The drug is a welcome addition to the antimalarial pharmacopoeia, although several challenges remain before it can be used widely in malaria endemic countries.